Crossbow Therapeutics

Private

Biotech developing TCR-mimetic antibody therapies (T-Bolt immunotherapies) to treat cancer. Lead candidate CBX-250 targets myeloid cancers with a Phase 1 trial underway and data expected by end of 2026.

Founders Mark DeMario

CEO Mark DeMario

Company

Founded

2020

Headquarters

Cambridge, United States

Financials

Total Funding

$107M

Sectors

Biotech

crossbowtx.com

Funding History

2 rounds

Series B Mar 13, 2026

$77M

Taiho Ventures (Lead) Arkin Bio Capital Sixty Degree Capital MPM BioImpact Pfizer Ventures BVF Partners Polaris Partners Eli Lilly

Series A Apr 1, 2023

$30M

MPM BioImpact (Lead) Pfizer Ventures BVF Partners Polaris Partners Eli Lilly

Funding data is compiled from multiple independent sources including company announcements, press coverage, and regulatory filings. While we strive for accuracy, amounts and dates may reflect reported figures at time of announcement.